⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761796 | 1.00 | — | — | |
| SCHEMBL854988 | 0.81 | — | — | |
| SCHEMBL382863 | 0.81 | — | — | |
| SCHEMBL856428 | 0.81 | — | — | |
| SCHEMBL6394337 | 0.69 | — | — | |
| SCHEMBL6390557 | 0.69 | — | — | |
| SCHEMBL6390553 | 0.69 | — | — | |
| SCHEMBL292425 | 0.65 | NOS3 (0.34) | — | |
| SCHEMBL4925273 | 0.65 | — | — | |
| SCHEMBL467961 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019736-A | Molecular gel compound designed based on cereblon protein and application thereof | 标新生物医药科技(上海)有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | claimed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | claimed |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | ABBVIE INC. (US) | 2018-12-18 | — | — | US | claimed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | claimed |
| EP-3286192-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co KG (DE) | 2018-02-28 | — | — | EP | claimed |
| EP-3256132-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-12-20 | — | — | EP | claimed |
| US-9828381-B2 | Substituted pyrazolopyrimidines and method of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-11-28 | — | — | US | claimed |
| WO-2016169995-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-27 | — | — | WO | claimed |
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-20 | — | — | US | claimed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | claimed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | claimed |
| US-20040132713-A1 | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2004050621-A2 | INDOL DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ALLERGAN, INC (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | claimed |
| US-6710040-B1 | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors | PFIZER INC. | 2004-03-23 | — | — | US | claimed |
| WO-2003101958-A2 | FLOURINATED CYCLIC AMIDES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | claimed |